Cardiovascular Drugs Practice Questions

Q: Which calcium channel blocker has the maximum effect on cardiac conduction?

Verapamil. **Explanation:** Calcium Channel Blockers (CCBs) are classified into two main categories based on their chemical structure and site of action: **Dihydropyridines** (acting primarily on vascular smooth muscle) and **Non-dihydropyridines** (acting primarily on the heart). **Why Verapamil is Correct:** Verapamil belongs to the **Phenylalkylamine** class. It has the highest affinity for the L-type calcium channels located in the **Sinoatrial (SA) and Atrioventricular (AV) nodes**. By blocking these channels, it significantly slows the rate of recovery of the channel, leading to a marked decrease in conduction velocity (negative dromotropy) and heart rate (negative chronotropy). Therefore, it has the **maximum effect on cardiac conduction** among all CCBs. **Analysis of Incorrect Options:** * **Phenylamine (A):** This is likely a distractor or a misspelling of Prenylamine (a legacy CCB). It does not possess the potent electrophysiological profile of Verapamil. * **Nifedipine (B):** A Dihydropyridine. It is a potent vasodilator with minimal effect on cardiac conduction at clinical doses. It often causes **reflex tachycardia** due to peripheral vasodilation. * **Diltiazem (D):** A Benzothiazepine. It occupies an intermediate position, affecting both vascular resistance and cardiac conduction. While it slows conduction, its effect is less potent than Verapamil. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** Verapamil is used for the termination of **Paroxysmal Supraventricular Tachycardia (PSVT)**. * **Contraindication:** Never give Verapamil to a patient on **Beta-blockers** or those with **Heart Failure**, as it can lead to severe bradycardia or heart block due to additive cardiosuppressant effects. * **Side Effect:** Constipation is the most common side effect of Verapamil.

Q: A 69-year-old man with heart failure and paroxysmal atrial fibrillation is prescribed amiodarone for maintenance of sinus rhythm. Which of the following is a known characteristic of amiodarone?

An active metabolite. **Explanation:** Amiodarone is a unique Class III antiarrhythmic drug with a complex pharmacokinetic profile, making it a high-yield topic for NEET-PG. **Why Option C is Correct:** Amiodarone is extensively metabolized in the liver by the CYP3A4 enzyme. Its primary metabolite is **Desethylamiodarone (DEA)**. This metabolite is pharmacologically **active** and possesses electrophysiological properties similar to the parent drug, contributing significantly to its long-term therapeutic and toxic effects. **Analysis of Incorrect Options:** * **A. Excellent oral absorption:** While amiodarone is absorbed from the GI tract, its bioavailability is inconsistent and incomplete (ranging from 30% to 70%) due to significant first-pass metabolism. * **B. A short half-life:** Amiodarone is highly lipophilic and sequesters in tissues (fat, liver, lungs). It has an exceptionally **long elimination half-life**, typically ranging from **25 to 60 days**. This necessitates the use of loading doses. * **D. Few drug interactions:** Amiodarone is a potent **inhibitor** of several P450 enzymes (CYP2C9, CYP2D6, CYP3A4) and P-glycoprotein. It has numerous clinically significant interactions, most notably increasing the plasma concentrations of **Warfarin, Digoxin, and Statins**. **NEET-PG High-Yield Pearls:** * **Iodine Content:** Amiodarone is structurally related to thyroxine and contains 37% iodine by weight, leading to thyroid dysfunction (Hypothyroidism/Wolff-Chaikoff or Hyperthyroidism/Jod-Basedow). * **Adverse Effects:** Remember the "6 P's": **P**ulmonary fibrosis (most serious), **P**hotodermatitis (Blue-grey skin), **P**rolonged QT interval (though rarely causes Torsades), **P**eripheral neuropathy, **P**apillary deposits (corneal microdeposits), and **P**roximally-acting thyroid issues. * **Drug of Choice:** It is the preferred antiarrhythmic for patients with heart failure or structural heart disease.

Q: Which beta-blocker can be safely used in hepatic disease?

Esmolol. **Explanation:** The correct answer is **Esmolol (Option A)**. The primary medical concept here is the site of drug metabolism. **Why Esmolol is the correct choice:** Esmolol is a unique, ultra-short-acting $\beta_1$-selective blocker. Unlike most beta-blockers that undergo hepatic metabolism, Esmolol is rapidly hydrolyzed by **red blood cell (RBC) esterases**. Because its clearance is independent of liver or kidney function, it can be safely used in patients with hepatic failure without the risk of drug accumulation or toxicity. **Analysis of Incorrect Options:** * **Betaxolol (Option B):** This is a cardioselective beta-blocker that undergoes significant hepatic metabolism. It is not the preferred choice in liver disease. * **Bisoprolol (Option C):** Bisoprolol is balanced in its elimination (50% hepatic and 50% renal). While safer than purely hepatic drugs, it still requires caution and potential dose adjustment in severe liver disease compared to Esmolol. * **Carvedilol (Option D):** This is a non-selective beta and alpha-1 blocker that is **extensively metabolized by the liver**. It is contraindicated or requires extreme caution in patients with hepatic impairment due to a significant increase in bioavailability and half-life. **High-Yield Clinical Pearls for NEET-PG:** * **Esmolol Half-life:** Approximately **9 minutes**, making it ideal for "on-off" control during hypertensive emergencies or intraoperative tachycardia. * **Metabolism Fact:** Always remember "Esmolol = Esterases." This is a frequent examiner favorite. * **Propranolol:** It has high lipid solubility and undergoes extensive first-pass metabolism in the liver; it is the drug of choice for preventing variceal bleeding in portal hypertension but must be dosed carefully. * **Atenolol & Nadolol:** These are primarily **renally excreted** and are the drugs of choice when avoiding hepatic metabolism is necessary, though Esmolol remains the safest in acute settings.

Q: A patient is taking an antianginal drug. Which of the following antianginal drugs is contraindicated with sildenafil?

Organic nitrates. **Explanation:** The correct answer is **Organic nitrates** (e.g., Nitroglycerin, Isosorbide dinitrate). **1. Mechanism of Interaction (The "Why"):** Organic nitrates act by releasing **Nitric Oxide (NO)**, which stimulates the enzyme **Guanylyl Cyclase**. This increases levels of **cyclic Guanosine Monophosphate (cGMP)**, leading to smooth muscle relaxation and vasodilation. **Sildenafil** (a PDE-5 inhibitor) prevents the breakdown of cGMP. When taken together, there is a synergistic accumulation of cGMP, leading to profound, unpredictable systemic vasodilation and **severe refractory hypotension**, which can result in myocardial infarction or death. **2. Analysis of Incorrect Options:** * **A. Calcium Channel Blockers (CCBs):** While both CCBs and sildenafil cause vasodilation, they do not share the same biochemical pathway (cGMP). They can be used together with caution, though blood pressure should be monitored. * **B. Beta-adrenergic Blockers:** These drugs decrease heart rate and contractility. There is no direct contraindication or dangerous synergistic effect with PDE-5 inhibitors. * **D. ACE Inhibitors:** These affect the Renin-Angiotensin-Aldosterone System (RAAS). While they lower blood pressure, they do not interact lethally with the NO-cGMP pathway. **3. High-Yield Clinical Pearls for NEET-PG:** * **Time Gap:** Sildenafil should not be taken within **24 hours** of a nitrate dose; Tadalafil (due to a longer half-life) requires a gap of at least **48 hours**. * **Management:** If a patient on sildenafil develops chest pain, nitrates must be avoided. Morphine or non-nitrate vasodilators are preferred. * **Other PDE-5 Inhibitors:** Vardenafil and Tadalafil share this same absolute contraindication with nitrates. * **Alpha-blockers:** Use caution when combining sildenafil with alpha-blockers (like Tamsulosin) due to the risk of additive orthostatic hypotension.

Q: Which vitamin is given in Type 2B Familial Hyperlipidemia?

Nicotinic acid. **Explanation:** **Nicotinic Acid (Vitamin B3/Niacin)** is the correct answer because it is a potent lipid-lowering agent [1]. In **Type 2B Familial Hyperlipidemia** (Combined Hyperlipidemia), there is an elevation of both LDL and VLDL (and consequently, triglycerides). **Mechanism of Action:** Niacin acts by inhibiting the enzyme **hormone-sensitive lipase** in adipose tissue. This reduces the breakdown of triglycerides into free fatty acids (FFA). Since the liver uses FFA to synthesize VLDL, a decrease in FFA leads to: 1. Decreased VLDL synthesis. 2. Decreased LDL levels (as LDL is a metabolic product of VLDL). 3. Increased HDL levels (by decreasing its clearance) [1]. This makes it highly effective for Type 2B, where both cholesterol and triglycerides are elevated [2]. **Why other options are incorrect:** * **Pantothenic acid (B5), Riboflavin (B2), and Thiamine (B1):** While these are essential water-soluble vitamins acting as co-factors in various metabolic pathways (e.g., Krebs cycle, decarboxylation), they do not possess significant lipid-lowering properties and have no therapeutic role in treating hyperlipidemias. **High-Yield Clinical Pearls for NEET-PG:** * **Most Potent:** Niacin is the most effective drug for **increasing HDL** levels. * **Side Effects:** The most common side effect is **cutaneous flushing** (mediated by Prostaglandin D2/E2; prevented by **Aspirin**). * **Metabolic Risks:** It can cause **hyperuricemia** (precipitating gout), **hyperglycemia** (caution in diabetics), and hepatotoxicity. * **Type 2B Phenotype:** Characterized by increased LDL + VLDL (Apo B-100 elevation).

Q: Digoxin toxicity is precipitated by all except?

Hepatic disease. **Explanation:** Digoxin is a cardiac glycoside with a narrow therapeutic index, meaning small changes in its metabolism or the body’s internal environment can easily lead to toxicity [3]. **Why Hepatic Disease is the Correct Answer:** Digoxin is primarily excreted **unchanged by the kidneys (approx. 60-80%)** [3]. It undergoes minimal hepatic metabolism. Therefore, hepatic impairment does not significantly affect digoxin levels and does not precipitate toxicity. In contrast, drugs like Digitoxin are metabolized by the liver and would be affected by hepatic disease [3]. **Analysis of Incorrect Options:** * **Electrolyte Disturbance:** This is the most common trigger. **Hypokalemia** is the classic precipitant because K+ and Digoxin compete for the same binding site on the Na+/K+ ATPase pump. Low K+ allows more Digoxin to bind. Hypomagnesemia and Hypercalcemia also increase toxicity risk. * **Acute Myocardial Infarction (MI):** Ischemic myocardium is more sensitive to the arrhythmogenic effects of Digoxin. The damaged tissue has altered electrical stability, lowering the threshold for Digoxin-induced arrhythmias. * **Renal Disease:** Since Digoxin is primarily cleared by the kidneys, any decrease in Glomerular Filtration Rate (GFR) leads to drug accumulation and toxicity [3]. Dose adjustment is mandatory in renal failure [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Most common ECG finding in toxicity:** Ventricular Bigeminy [2]. * **Most characteristic ECG finding:** Bidirectional Ventricular Tachycardia. * **Early signs of toxicity:** Gastrointestinal symptoms (anorexia, nausea, vomiting). * **Visual disturbance:** Xanthopsia (yellowish-green vision). * **Antidote:** Digoxin Immune Fab (Digibind). * **Drug Interactions:** Quinidine, Verapamil, and Amiodarone increase Digoxin levels by displacing it from tissue binding sites and reducing renal clearance [1].

Q: What effect does digitalis have when given in atrial flutter?

Atrial fibrillation. Digitalis (Digoxin) is a unique anti-arrhythmic agent that exerts its effects primarily through the enhancement of vagal tone (parasympathomimetic effect). **Why Atrial Fibrillation is the Correct Answer:** In **Atrial Flutter**, the atria beat at a rapid, organized rate (typically 250–350 bpm). Digitalis acts by **shortening the atrial refractory period** and increasing the conduction velocity in the atrial muscle [1]. This "pro-arrhythmic" effect on the atria tends to convert the organized, large-circuit reentry of flutter into the disorganized, multiple-micro-reentry circuits characteristic of **Atrial Fibrillation (AF)** [1, 2]. While this might seem counterintuitive, converting flutter to AF is often clinically acceptable because Digitalis simultaneously **increases the refractory period of the AV node** [1]. This slows the ventricular rate, protecting the ventricles from the rapid atrial impulses and providing symptomatic relief. **Analysis of Incorrect Options:** * **B. Atrial Tachycardia:** Digitalis is used to treat certain supraventricular tachycardias; it does not typically convert flutter into a simple tachycardia. * **C. Atrial Asystole:** Digitalis does not cause the atria to stop beating entirely; its effect is to change the rhythm, not induce standstill. * **D. Atrial Bigeminy:** While Digitalis toxicity can cause ventricular bigeminy (due to increased automaticity), it is not the characteristic outcome of treating atrial flutter. **High-Yield NEET-PG Pearls:** * **Mechanism:** Digoxin inhibits the Na+/K+ ATPase pump, but its anti-arrhythmic effect is via **vagal stimulation**. * **ECG Changes:** Look for the "reverse tick" or "Sagging ST segment" (Digitalis effect). * **Toxicity:** The most common arrhythmia in Digoxin toxicity is **PVCs**, but the most characteristic/pathognomonic is **PAT with AV block**. * **Electrolytes:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose to Digoxin toxicity.

Q: Which calcium channel sensitizer is approved for the treatment of congestive heart failure?

Levosimendan. **Explanation:** **Levosimendan** is the correct answer because it is a unique "Inodilator" that acts primarily as a **calcium channel sensitizer**. It binds to cardiac troponin C in a calcium-dependent manner, increasing the sensitivity of the contractile apparatus to existing intracellular calcium. This enhances myocardial contractility (inotropy) without increasing intracellular calcium levels, thereby avoiding the risk of arrhythmias and increased myocardial oxygen demand associated with traditional inotropes like Dobutamine. Additionally, it opens ATP-sensitive potassium channels, leading to peripheral vasodilation. **Analysis of Incorrect Options:** * **Nesiritide:** This is a recombinant form of human B-type Natriuretic Peptide (BNP). It acts via cGMP to cause vasodilation and natriuresis but does not have calcium-sensitizing properties. * **Vasopressin:** An antidiuretic hormone (ADH) analogue used primarily as a vasoconstrictor in distributive shock; it would worsen heart failure by increasing afterload. * **Nitroprusside:** A potent vasodilator that acts by releasing Nitric Oxide (NO). It reduces both preload and afterload but has no direct effect on cardiac contractility or calcium sensitivity. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Levosimendan increases inotropy *without* increasing myocardial oxygen consumption ($MVO_2$). * **Dual Action:** It is an **Inodilator** (Inotrope + Vasodilator). * **Indication:** Short-term management of acutely decompensated severe chronic heart failure. * **Side Effects:** Hypotension (due to vasodilation) and headache. * **Comparison:** Unlike Milrinone (a PDE-3 inhibitor), Levosimendan does not significantly increase the risk of calcium-overload-induced arrhythmias.

Question 1

Which calcium channel blocker has the maximum effect on cardiac conduction?

Accepted Answer

Verapamil

Answer

Phenylamine

Answer

Nifedipine

Answer

Diltiazem

Question 2

A 69-year-old man with heart failure and paroxysmal atrial fibrillation is prescribed amiodarone for maintenance of sinus rhythm. Which of the following is a known characteristic of amiodarone?

Accepted Answer

An active metabolite

Answer

Excellent oral absorption

Answer

A short half-life

Answer

Few drug interactions

Question 3

Which beta-blocker can be safely used in hepatic disease?

Accepted Answer

Esmolol

Answer

Betaxolol

Answer

Bisoprolol

Answer

Carvedilol

Question 4

A patient is taking an antianginal drug. Which of the following antianginal drugs is contraindicated with sildenafil?

Accepted Answer

Organic nitrates

Answer

Calcium channel blockers

Answer

Beta-adrenergic blockers

Answer

Angiotensin-converting enzyme inhibitors

Question 5

Which vitamin is given in Type 2B Familial Hyperlipidemia?

Accepted Answer

Nicotinic acid

Answer

Pantothenic acid

Answer

Riboflavin

Answer

Thiamine

Question 6

Digoxin is contraindicated in which of the following conditions?

Accepted Answer

Hypertrophic obstructive cardiomyopathy

Answer

Supraventricular tachycardia

Answer

Atrial fibrillation

Answer

Congestive heart failure

Question 7

Digoxin toxicity is precipitated by all except?

Accepted Answer

Hepatic disease

Answer

Electrolyte disturbance

Answer

Acute myocardial infarction

Answer

Renal disease

Question 8

What is the drug of choice in paroxysmal supraventricular tachycardia?

Accepted Answer

Adenosine

Answer

Digoxin

Answer

Nifedipine

Answer

Esmolol

Question 9

What effect does digitalis have when given in atrial flutter?

Accepted Answer

Atrial fibrillation

Answer

Atrial tachycardia

Answer

Atrial asystole

Answer

Atrial bigeminy

Question 10

Which calcium channel sensitizer is approved for the treatment of congestive heart failure?

Accepted Answer

Levosimendan

Answer

Nesitritide

Answer

Vasopressin

Answer

Nitroprusside

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?